Pfizer Inc. (NYSE:PFE) Shares Sold by Commonwealth Retirement Investments LLC

Commonwealth Retirement Investments LLC decreased its stake in Pfizer Inc. (NYSE:PFE) by 13.3% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 41,957 shares of the biopharmaceutical company’s stock after selling 6,417 shares during the period. Commonwealth Retirement Investments LLC’s holdings in Pfizer were worth $1,214,000 as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in PFE. Marshall Wace LLP increased its stake in Pfizer by 279.3% in the 2nd quarter. Marshall Wace LLP now owns 5,378,173 shares of the biopharmaceutical company’s stock valued at $150,481,000 after purchasing an additional 8,378,173 shares in the last quarter. Swedbank AB purchased a new position in shares of Pfizer in the first quarter valued at $172,902,000. International Assets Investment Management LLC acquired a new position in shares of Pfizer during the 3rd quarter worth $146,481,000. 1832 Asset Management L.P. boosted its position in shares of Pfizer by 24,961.6% in the 2nd quarter. 1832 Asset Management L.P. now owns 2,497,886 shares of the biopharmaceutical company’s stock worth $69,891,000 after buying an additional 2,487,919 shares in the last quarter. Finally, Robeco Institutional Asset Management B.V. increased its holdings in Pfizer by 120.7% during the 3rd quarter. Robeco Institutional Asset Management B.V. now owns 4,498,313 shares of the biopharmaceutical company’s stock valued at $130,181,000 after acquiring an additional 2,459,666 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Trading Down 0.1 %

Shares of PFE traded down $0.02 during trading hours on Tuesday, hitting $26.22. The stock had a trading volume of 11,207,657 shares, compared to its average volume of 37,534,734. The company’s fifty day simple moving average is $28.84 and its 200 day simple moving average is $28.67. Pfizer Inc. has a 12-month low of $25.20 and a 12-month high of $31.54. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.60 and a current ratio of 1.00. The firm has a market cap of $148.59 billion, a P/E ratio of 35.46, a P/E/G ratio of 0.85 and a beta of 0.67.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.64 by $0.42. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The business had revenue of $17.70 billion during the quarter, compared to analysts’ expectations of $14.92 billion. During the same quarter in the previous year, the business earned ($0.17) EPS. The company’s revenue for the quarter was up 31.2% on a year-over-year basis. Equities research analysts forecast that Pfizer Inc. will post 2.96 EPS for the current fiscal year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 2nd. Investors of record on Friday, November 8th will be given a dividend of $0.42 per share. The ex-dividend date of this dividend is Friday, November 8th. This represents a $1.68 dividend on an annualized basis and a yield of 6.41%. Pfizer’s dividend payout ratio (DPR) is 227.03%.

Analyst Ratings Changes

Several analysts have recently commented on PFE shares. Daiwa Capital Markets upgraded shares of Pfizer from a “neutral” rating to an “outperform” rating and increased their price target for the company from $28.00 to $34.00 in a research report on Wednesday, August 7th. Wells Fargo & Company increased their target price on Pfizer from $28.00 to $30.00 and gave the company an “equal weight” rating in a report on Wednesday, July 31st. StockNews.com upgraded Pfizer from a “hold” rating to a “buy” rating in a research report on Wednesday, October 9th. Citigroup initiated coverage on Pfizer in a research report on Friday, October 25th. They set a “neutral” rating and a $30.00 price objective for the company. Finally, Daiwa America upgraded shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, August 7th. Eight research analysts have rated the stock with a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, Pfizer currently has a consensus rating of “Moderate Buy” and an average target price of $33.58.

Insider Activity at Pfizer

In related news, Director Scott Gottlieb purchased 1,000 shares of Pfizer stock in a transaction that occurred on Wednesday, October 30th. The shares were purchased at an average cost of $28.24 per share, with a total value of $28,240.00. Following the transaction, the director now owns 10,000 shares of the company’s stock, valued at approximately $282,400. The trade was a 0.00 % increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. 0.06% of the stock is owned by insiders.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.